Global Market Boom for Generic Drugs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Global Market Boom for Generic Drugs


ePT--the Electronic Newsletter of Pharmaceutical Technology

The generic-drugs market is poised to experience strong growth as key blockbuster products go off patent, but companies looking to benefit from this will have to be careful about the product segments where they compete, according to a report from Frost & Sullivan.

The report, Generic Pharmaceuticals Market — A Global Analysis, explains that drugs worth $150 billion will go off-patent between 2010 and 2017, helping to propel the generic-drugs market from revenues of $123.85 billion in 2010 to an estimated $231 billion in 2017. However, as competition intensifies, generic-drug manufacturers will need to carefully consider their product segments and the appropriate time for market launch. Companies will also have to deal with increasingly stringent regulations and price-control measures from governments, mainly being driven as a result of the aging population and the prevalence of chronic diseases.

“Large multinational generic firms need to adopt a differentiated approach by opting for products with technologically challenging formulations, products which require significant regulatory support and products with limited availability of active pharmaceutical ingredients,” Aiswariya Chidambaram, a research analyst at Frost & Sullivan, said in a press statement.

According to the report, some companies have forged strategic alliances with branded pharma for the marketing rights and exclusivity to certain generic blockbusters, such as Lipitor and Crestor, among others. Many market-leading generic-drugs companies, such as Teva, Sandoz, and Mylan, are also increasingly focusing more on biosimilars, which provide a competitive edge and offer potentially huge profit margins. In addition, difficult-to-produce generic drugs and speciality products are also attracting greater attention. Aiswariya notes that, “Small and medium-sized firms should focus on products with relatively higher profit margins.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here